Evidence map›Paper›PMID 34291111›Full record

ArticleERJ open research2021

Feasibility of comprehensive genotyping specimens from radial endobronchial ultrasonography and electromagnetic navigation bronchoscopy.

Maxime Robin, Laurent Mhanna, Leonor Chaltiel, Gavin Plat, Valentin Héluain, Céline Basset, Julie Meilleroux, Thomas Filleron, Julien Mazières, Christophe Hermant and 1 more

Open access · goldAbstract read
In one paragraph

Article in ERJ open research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.9field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 5 institutions in 1 country.

Maxime RobinPulmonology Dept, Larrey University Hospital, Toulouse, France.
Laurent MhannaPulmonology Dept, Larrey University Hospital, Toulouse, France.
Leonor ChaltielBiostatistics Dept, Institut Claudius Regaud, Toulouse University Cancer Institute (IUCT-O), Toulouse, France.
Gavin PlatPulmonology Dept, Larrey University Hospital, Toulouse, France.ORCID https://orcid.org/0000-0001-5374-6541
Valentin HéluainPulmonology Dept, Larrey University Hospital, Toulouse, France.
Céline BassetCytology Dept, IUCT-O, Toulouse, France.
Julie MeillerouxPathology Dept, IUCT-O, Toulouse, France.
Thomas FilleronBiostatistics Dept, Institut Claudius Regaud, Toulouse University Cancer Institute (IUCT-O), Toulouse, France.
Julien MazièresPulmonology Dept, Larrey University Hospital, Toulouse, France.
Christophe HermantPulmonology Dept, Larrey University Hospital, Toulouse, France.
Nicolas GuibertPulmonology Dept, Larrey University Hospital, Toulouse, France.
Hôpital Larrey · FRUniversité Toulouse III - Paul Sabatier · FRInstitut universitaire du cancer de Toulouse Oncopole · FRAix-Marseille Université · FRUniversité Paris Cité · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionMini-invasive bronchoscopic techniques (such as radial endobronchial ultrasonography (rEBUS) and electromagnetic navigation (EMN)) have been developed to reach the peripheral lung but result in small samples. The feasibility of an adequate molecular testing from these specimens has been very little studied.

methodsWe retrospectively reviewed EMN and rEBUS procedures performed in patients diagnosed with lung cancer in our institution in 2017 and 2018. We analysed the sensitivity for rEBUS and EMN and each sampling method, and the feasibility of a comprehensive molecular testing.

resultsIn total, 317 rEBUS and 14 EMN were performed. Median sizes of tumours were 16 and 32 mm for EMN and rEBUS, respectively. Overall sensitivity for rEBUS and EMN was 84.3%. Cytology was found to be complementary with biopsies, with 13.3% of cancer diagnosed on cytology while biopsies were negative. Complication rate was 2.4% (pneumothorax 1.5%, mild haemoptysis 0.9%). Genotyping (immunohistochemistry for

conclusionrEBUS and EMN are sensitive and safe procedures that result in limited samples, often not suitable for genotyping, highlighting the importance of integrating liquid biopsy in routine testing.

Identifiers

PMID34291111
PMCPMC8287134
OpenAlexW3165343533

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.